VCM
RAPP

Versant Capital Management’s Rapport Therapeutics RAPP Stock Holding History

Versant Capital Management’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13K Hold
27
– – ﹤0.01% 2629
2026
Q1 		$845 Buy
+27
New +$759 ﹤0.01% 2671

Other funds holding RAPP

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
CPW
Catalyst Private Wealth San Mateo, California $207M AUM 11.77% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Versant Capital Management's RAPP Position: Q2 2026 in Review

Versant Capital Management held its Rapport Therapeutics (RAPP) position steady in Q2 2026 at 27 shares worth $1.13K. The position accounts for ﹤0.01% of the portfolio, ranked #2629.

Versant Capital Management first reported a position in RAPP in Q1 2026 and has held it in 2 quarters since. 13 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Versant Capital Management held 27 shares of Rapport Therapeutics worth $1.13K as of Q2 2026.
  • Versant Capital Management left its Rapport Therapeutics share count unchanged in Q2 2026.
  • Rapport Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2629 holding.
  • Versant Capital Management first reported a position in Rapport Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 13 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.